Developer docs
API playgroundTry for free, no card

Search company profiles

MedReleaf

Full company profile

uuid00062ru

Namestring
MedReleaf
Legal namestring
Aurora Cannabis Inc.
Websiteurl
medreleaf.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

MedReleaf is a Canadian licensed producer of medical cannabis and a wholly owned subsidiary of Aurora Cannabis Inc. (NYSE: ACB), with the operational center of gravity shifted to its MedReleaf Australia entity serving Australia and New Zealand. It manufactures and distributes a full medicinal cannabis portfolio including dried flower, pre-rolls, capsules, oils, concentrates, vapes, edibles, beverages, and topicals, and operates a multi-brand shelf including MedReleaf, Aurora, IndiMed, Whistler Cannabis Co., and CraftPlant. Production is conducted at Aurora's EU-GMP and TGA-GMP certified facilities in Canada using the parent company's proprietary cannabis genetics, which provides the pharmaceutical-grade quality assurance required to supply Australian and New Zealand regulated markets.

The business model is B2B-led rather than direct-to-consumer. In Australia, MedReleaf reaches patients through two parallel pharmacy-channel partnerships: Leafio, the wholesale distribution arm of Montu Australia, which services more than 4,000 pharmacies nationwide; and Vitura Health's Canview online platform, distributed through the Burleigh Heads Cannabis network across approximately 4,700 pharmacies, with Vitura estimating the deal could contribute up to $15 million in additional annual revenue. Marketing is concentrated in clinician education and product innovation rather than consumer advertising, and end customers are medical cannabis patients and the healthcare providers who prescribe to them. The company was originally founded in 2014 and was acquired by Aurora Cannabis in 2019, and the corporate, manufacturing, and distribution footprint is small (51-100 employees) relative to its pharmacy reach, reflecting a lean, channel-partner-driven operating model.

Underlying demand is supported by the global medical cannabis market context ($38.05 billion in 2025, growing at 18.84% CAGR per cited market data), with Australia cited as one of Aurora's largest international medical cannabis markets and recent product launches (THC flower in New Zealand, resin cartridges in Australia) extending the category mix. Revenue, pricing, and segment economics are not publicly disclosed at the MedReleaf level, leaving investor visibility dependent on parent Aurora's consolidated reporting and partner commentary such as Vitura's deal estimate.

Short descriptiontext

MedReleaf is a wholly owned subsidiary of Aurora Cannabis that produces and distributes EU-GMP and TGA-GMP certified medicinal cannabis under multiple brands across Australia and New Zealand, reaching patients through pharmacy wholesale partners Leafio and Vitura Health's Canview platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarkham, Canada
HQ citystring
Markham
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis products, cannabis cultivation production, pharmaceutical grade cannabis, cannabis distribution pharmacy, cannabis brand portfolio
Industry3 codes
PRIMARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medical Cannabis
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medicinal Cannabis Product Sales
TypeOne Time License
Description

MedReleaf generates revenue through the sale of its medicinal cannabis product portfolio including dried flower, oils, capsules, concentrates, vapes, edibles, and beverages under brands including MedReleaf, IndiMed, Aurora, and Whistler Cannabis Co.

smallcaps.com.au
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1IndiMed
Description

Medicinal cannabis brand under MedReleaf portfolio

smallcaps.com.au
+3 more records
Core offering1 text field

MedReleaf is a Canadian licensed producer and distributor of medical cannabis, operating as a wholly owned subsidiary of Aurora Cannabis Inc. The company sells a full suite of medicinal cannabis products under brands including MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant — spanning dried flower, oils, capsules, concentrates, vapes, edibles, and beverages — manufactured at EU-GMP and TGA-GMP certified facilities and distributed through pharmacy networks in Australia and New Zealand.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Up to $15 million potential additional annual revenue for distribution partner
+1 more record
Product overview1 text field

MedReleaf is a wholly owned subsidiary of Canadian-based Aurora Cannabis Inc. (NYSE: ACB) offering medicinal cannabis products under multiple brands including MedReleaf, Aurora, IndiMed, Whistler Cannabis Co., and CraftPlant. The company operates as part of Aurora's portfolio of medical cannabis brands distributed through various channels in Australia, New Zealand, and Canada. MedReleaf products span the full range of cannabis product formats including dried flower, pre-rolls, capsules, oils, concentrates, vapes, edibles, beverages, and topicals. Products are manufactured at Aurora's EU-GMP and TGA-GMP certified facilities in Canada using proprietary genetics. Distribution partnerships with Leafio (4,000+ pharmacies) and Vitura Health's Canview platform (4,700+ pharmacies) expand patient access across Australia.

Product and service6 records
1MedReleaf brand medical cannabis products
CategoryMedical cannabis sub-brand
2Aurora medical cannabis products
CategoryMedical cannabis sub-brand
3IndiMed medicinal cannabis products
CategoryMedical cannabis sub-brand
4Whistler Cannabis Co. medical cannabis products
CategoryMedical cannabis sub-brand
5CraftPlant medical cannabis products
CategoryMedical cannabis sub-brand
6New Zealand THC flower and Australia resin cartridges launch
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-17
Description

Vitura Health signed a commercial distribution agreement with MedReleaf Australia to make MedReleaf's full suite of medicinal cannabis products available on Vitura's Canview online platform, distributed through the Burleigh Heads Cannabis nationwide network. Vitura estimates the deal could contribute up to $15 million in additional annual revenue, subject to patient demand and regulatory conditions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-02
Description

MedReleaf Australia's distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, to expand patient access to medical cannabis products across Australia. Aurora's medical cannabis brands including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed will be distributed through Leafio's nationwide supply chain servicing over 4,000 pharmacies. The partnership aims to enhance clinician education, product innovation, and improve patient outcomes.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian licensed producer of medical cannabis, including a portfolio of dried flower, oils, and pre-rolls, with international distribution. Direct competitor in supplying Australian pharmacies with EU-GMP certified product.

TypeBroad incumbent
Description

Parent company of MedReleaf and a major global cannabis producer with operations across medical and consumer markets. Directly comparable as a medical cannabis cultivator and brand portfolio operator spanning dried flower, oils, capsules, vapes, and edibles.

TypeDirect peer
Description

Australian licensed medical cannabis cultivator and manufacturer. Comparable as a domestic producer supplying Australian pharmacy networks with medical-grade cannabis products, competing with MedReleaf's imported and locally distributed offerings.

TypeDirect peer
Description

Australian-based medical cannabis producer with strong domestic distribution through pharmacy networks. Competes directly with MedReleaf Australia for shelf space and prescriber relationships in the Australian market.

TypeEmerging player
Description

Australian medical cannabis distribution and patient services company operating the Leafio wholesale network. While primarily a distributor and MedReleaf partner, Montu's vertical integration ambitions make it a comparable and potentially competing operator in the Australian medical cannabis channel.

TypeDirect peer
Description

Canadian licensed producer with international medical cannabis operations including Australia. Comparable in offering branded medical cannabis (dried flower, oils, capsules) into Australian pharmacy channels with similar distribution partnerships.

TypeDirect peer
Description

Australian medical cannabis company producing and distributing a range of cannabis products (flower, oils, vapes) through pharmacy channels. Directly comparable in target customer (Australian patients), product formats, and pharmacy-led GTM.

TypeEmerging player
Description

Australian health and wellness company operating the Canview B2B platform and Burleigh Heads Cannabis pharmacy network. Functions as a key MedReleaf distribution partner, and its scale across 4,700+ Australian pharmacies makes it a critical peer in the medical cannabis distribution channel.

TypeBroad incumbent
Description

Canadian-licensed cannabis producer with international medical cannabis ambitions and a multi-format product portfolio. Comparable as a peer Canadian LP with EU-GMP capabilities targeting international medical markets, though with less concentrated focus on Australia.

10Tilray Brands
TypeDirect peer
Description

Global cannabis company with significant Australian medical cannabis distribution footprint through its Tilray Medical brand. Directly competes with MedReleaf in supplying EU-GMP medical cannabis to Australian pharmacy networks and prescribers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MedReleaf

Medical Cannabismedreleaf.com

MedReleaf is a wholly owned subsidiary of Aurora Cannabis that produces and distributes EU-GMP and TGA-GMP certified medicinal cannabis under multiple brands across Australia and New Zealand, reaching patients through pharmacy wholesale partners Leafio and Vitura Health's Canview platform.

What MedReleaf does

MedReleaf is a Canadian licensed producer of medical cannabis and a wholly owned subsidiary of Aurora Cannabis Inc. (NYSE: ACB), with the operational center of gravity shifted to its MedReleaf Australia entity serving Australia and New Zealand. It manufactures and distributes a full medicinal cannabis portfolio including dried flower, pre-rolls, capsules, oils, concentrates, vapes, edibles, beverages, and topicals, and operates a multi-brand shelf including MedReleaf, Aurora, IndiMed, Whistler Cannabis Co., and CraftPlant. Production is conducted at Aurora's EU-GMP and TGA-GMP certified facilities in Canada using the parent company's proprietary cannabis genetics, which provides the pharmaceutical-grade quality assurance required to supply Australian and New Zealand regulated markets.

The business model is B2B-led rather than direct-to-consumer. In Australia, MedReleaf reaches patients through two parallel pharmacy-channel partnerships: Leafio, the wholesale distribution arm of Montu Australia, which services more than 4,000 pharmacies nationwide; and Vitura Health's Canview online platform, distributed through the Burleigh Heads Cannabis network across approximately 4,700 pharmacies, with Vitura estimating the deal could contribute up to $15 million in additional annual revenue. Marketing is concentrated in clinician education and product innovation rather than consumer advertising, and end customers are medical cannabis patients and the healthcare providers who prescribe to them. The company was originally founded in 2014 and was acquired by Aurora Cannabis in 2019, and the corporate, manufacturing, and distribution footprint is small (51-100 employees) relative to its pharmacy reach, reflecting a lean, channel-partner-driven operating model.

Underlying demand is supported by the global medical cannabis market context ($38.05 billion in 2025, growing at 18.84% CAGR per cited market data), with Australia cited as one of Aurora's largest international medical cannabis markets and recent product launches (THC flower in New Zealand, resin cartridges in Australia) extending the category mix. Revenue, pricing, and segment economics are not publicly disclosed at the MedReleaf level, leaving investor visibility dependent on parent Aurora's consolidated reporting and partner commentary such as Vitura's deal estimate.

MedReleaf firmographics

Firmographics
Name
MedReleaf
Legal name
Aurora Cannabis Inc.
Website
https://medreleaf.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
MedReleaf is a wholly owned subsidiary of Aurora Cannabis that produces and distributes EU-GMP and TGA-GMP certified medicinal cannabis under multiple brands across Australia and New Zealand, reaching patients through pharmacy wholesale partners Leafio and Vitura Health's Canview platform.
Ownership category
akta.pro rank

MedReleaf industry classification

Industry
Product category
Medical Cannabis
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medical cannabis products
  • Cannabis cultivation production
  • Pharmaceutical grade cannabis
  • Cannabis distribution pharmacy
  • Cannabis brand portfolio

Where MedReleaf is headquartered

Location

Headquarters

HQ city
Markham
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

MedReleaf business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Medicinal Cannabis Product Sales: MedReleaf generates revenue through the sale of its medicinal cannabis product portfolio including dried flower, oils, capsules, concentrates, vapes, edibles, and beverages under brands including MedReleaf, IndiMed, Aurora, and Whistler Cannabis Co.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

MedReleaf product offering

Product offering

Core offering

MedReleaf is a Canadian licensed producer and distributor of medical cannabis, operating as a wholly owned subsidiary of Aurora Cannabis Inc. The company sells a full suite of medicinal cannabis products under brands including MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant — spanning dried flower, oils, capsules, concentrates, vapes, edibles, and beverages — manufactured at EU-GMP and TGA-GMP certified facilities and distributed through pharmacy networks in Australia and New Zealand.

Product overview

MedReleaf is a wholly owned subsidiary of Canadian-based Aurora Cannabis Inc. (NYSE: ACB) offering medicinal cannabis products under multiple brands including MedReleaf, Aurora, IndiMed, Whistler Cannabis Co., and CraftPlant. The company operates as part of Aurora's portfolio of medical cannabis brands distributed through various channels in Australia, New Zealand, and Canada. MedReleaf products span the full range of cannabis product formats including dried flower, pre-rolls, capsules, oils, concentrates, vapes, edibles, beverages, and topicals. Products are manufactured at Aurora's EU-GMP and TGA-GMP certified facilities in Canada using proprietary genetics. Distribution partnerships with Leafio (4,000+ pharmacies) and Vitura Health's Canview platform (4,700+ pharmacies) expand patient access across Australia.

Differentiator

Problem solved

Functional benefit

Brands

  • IndiMed: Medicinal cannabis brand under MedReleaf portfolio
  • Whistler Cannabis Co.
  • CraftPlant
  • MedReleaf

Products and services

  • MedReleaf brand medical cannabis products
  • Aurora medical cannabis products
  • IndiMed medicinal cannabis products
  • Whistler Cannabis Co. medical cannabis products
  • CraftPlant medical cannabis products
  • New Zealand THC flower and Australia resin cartridges launch

Quantifiable outcome

  • Up to $15 million potential additional annual revenue for distribution partner
  • +1 more outcomes

Companies that use MedReleaf

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

MedReleaf technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

MedReleaf partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Vitura HealthcoreChannel Partner/ Reseller/ Distributor · 17 March 2026Vitura Health signed a commercial distribution agreement with MedReleaf Australia to make MedReleaf's full suite of medicinal cannabis products available on Vitura's Canview online platform, distributed through the Burleigh Heads Cannabis nationwide network. Vitura estimates the deal could contribute up to $15 million in additional annual revenue, subject to patient demand and regulatory conditions.
  • Leafio Australia (Montu)coreChannel Partner/ Reseller/ Distributor · 2 December 2025MedReleaf Australia's distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, to expand patient access to medical cannabis products across Australia. Aurora's medical cannabis brands including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed will be distributed through Leafio's nationwide supply chain servicing over 4,000 pharmacies. The partnership aims to enhance clinician education, product innovation, and improve patient outcomes.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

MedReleaf competitors and assessment

Company assessment

Direct peers

  • OrganiGram Holdings: Canadian licensed producer of medical cannabis, including a portfolio of dried flower, oils, and pre-rolls, with international distribution. Direct competitor in supplying Australian pharmacies with EU-GMP certified product.
  • Cann Group Limited: Australian licensed medical cannabis cultivator and manufacturer. Comparable as a domestic producer supplying Australian pharmacy networks with medical-grade cannabis products, competing with MedReleaf's imported and locally distributed offerings.
  • Little Green Pharma: Australian-based medical cannabis producer with strong domestic distribution through pharmacy networks. Competes directly with MedReleaf Australia for shelf space and prescriber relationships in the Australian market.
  • Canopy Growth Corporation: Canadian licensed producer with international medical cannabis operations including Australia. Comparable in offering branded medical cannabis (dried flower, oils, capsules) into Australian pharmacy channels with similar distribution partnerships.
  • Althea Group Holdings: Australian medical cannabis company producing and distributing a range of cannabis products (flower, oils, vapes) through pharmacy channels. Directly comparable in target customer (Australian patients), product formats, and pharmacy-led GTM.
  • Tilray Brands: Global cannabis company with significant Australian medical cannabis distribution footprint through its Tilray Medical brand. Directly competes with MedReleaf in supplying EU-GMP medical cannabis to Australian pharmacy networks and prescribers.

Broad incumbents

  • Aurora Cannabis Inc. Parent company of MedReleaf and a major global cannabis producer with operations across medical and consumer markets. Directly comparable as a medical cannabis cultivator and brand portfolio operator spanning dried flower, oils, capsules, vapes, and edibles.
  • Cronos Group: Canadian-licensed cannabis producer with international medical cannabis ambitions and a multi-format product portfolio. Comparable as a peer Canadian LP with EU-GMP capabilities targeting international medical markets, though with less concentrated focus on Australia.

Emerging players

  • Montu Group (parent of Leafio): Australian medical cannabis distribution and patient services company operating the Leafio wholesale network. While primarily a distributor and MedReleaf partner, Montu's vertical integration ambitions make it a comparable and potentially competing operator in the Australian medical cannabis channel.
  • Vitura Health: Australian health and wellness company operating the Canview B2B platform and Burleigh Heads Cannabis pharmacy network. Functions as a key MedReleaf distribution partner, and its scale across 4,700+ Australian pharmacies makes it a critical peer in the medical cannabis distribution channel.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

MedReleaf social profiles

Digital presence

MedReleaf compliance and trust

Trust signal

Compliance2 records

MedReleaf financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MedReleaf leadership team

Management profile

Number of profiles

Profiles4 records

MedReleaf subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MedReleaf funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MedReleaf M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedReleaf

What does MedReleaf do?

MedReleaf is a Canadian licensed producer and distributor of medical cannabis, operating as a wholly owned subsidiary of Aurora Cannabis Inc. The company sells a full suite of medicinal cannabis products under brands including MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant — spanning dried flower, oils, capsules, concentrates, vapes, edibles, and beverages — manufactured at EU-GMP and TGA-GMP certified facilities and distributed through pharmacy networks in Australia and New Zealand.

Is MedReleaf a public or private company?

MedReleaf is a private company. It is classified as corporate owned and is currently operating.

When was MedReleaf founded?

MedReleaf was founded in 2017. It employs 11 to 50 people.

Where is MedReleaf based?

MedReleaf is headquartered in Markham, Canada, in the North America region.

How does MedReleaf make money?

One revenue line is on record: medicinal Cannabis Product Sales.

Who are MedReleaf's main competitors?

Direct peers on record are OrganiGram Holdings, Cann Group Limited, Little Green Pharma, Canopy Growth Corporation, Althea Group Holdings and Tilray Brands. Broad incumbents are Aurora Cannabis Inc. and Cronos Group. Emerging players are Montu Group (parent of Leafio) and Vitura Health.

Does MedReleaf have an API?

No public API is recorded for MedReleaf.

What industry is MedReleaf in?

MedReleaf's product category is Medical Cannabis. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAGAG, Medical Cannabis Delivery & Online Ordering. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Small CapsVitura Health Signs Online Distribution Deal for MedReleaf Medicinal Cannabis ProductsVitura Health (ASX: VIT) has signed a commercial distribution agreement with MedReleaf Australia to make MedReleaf's full suite of medicinal cannabis products available on Vitura's Canview online platform, distributed through the Burleigh Heads Cannabis nationwide network. MedReleaf is a wholly owned subsidiary of Canadian-based Aurora Cannabis and offers products under brands including MedReleaf, IndiMed, Aurora, and Whistler Cannabis Co. Vitura estimates the deal could contribute up to $15 million in additional annual revenue, subject to patient demand and regulatory conditions, while the Canview platform currently represents approximately 4,700 Australian pharmacies.YahooAurora Announces Distribution Partnership with Leafio AustraliaAurora Cannabis Inc. announced that its wholly owned subsidiary MedReleaf Australia has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia, to expand patient access to medical cannabis products across Australia. Under the agreement, Aurora's medical cannabis brands including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed will be distributed through Leafio's nationwide supply chain servicing over 4,000 pharmacies. The partnership aims to enhance clinician education, product innovation, and improve patient outcomes in the Australian medical cannabis market.PR NewswireAurora Announces Medical Product Advancements from Leading Cannabis Research FacilityAurora Cannabis Inc. announced new medical cannabis product advancements developed at its Aurora Coast research facility in Comox, British Columbia, Canada. The product lineup includes new CBD and THC products across its MedReleaf and WMMC brands, featuring strains with varying potency levels ranging from 20-31% THC content. The company emphasized its commitment to cannabis innovation and patient access through its medical eCommerce platform.PR NewswireAurora Expands Strains for Heroes Offerings Designed for Veterans, by VeteransAurora Cannabis Inc. announced the launch of Honour, a new premium indica cannabis cultivar with 20-26% THC, as the second product in its Strain for Heroes portfolio designed specifically for Canadian veterans. Five per cent of net profits from Strain for Heroes product sales will support veteran organizations across Canada, including Wounded Warriors, The Post Traumatic Growth Association, The Valhalla Project, and Quilts of Valour. The Honour strain, available under the MedReleaf brand in 15g dried flower format with pre-rolls launching in October, was developed with direct input from Canadian veterans who also visited Aurora's research facility in Comox, BC.PR NewswireAurora Launches New Medical Flower Product, Valour - Designed for Veterans, by VeteransAurora Cannabis Inc. announced the launch of Valour, a new premium indica cannabis cultivar designed for veterans and developed alongside the veteran community under the MedReleaf brand. Five per cent of net profits from Valour sales, capped at $200,000 per year, will support veteran-focused organizations across Canada including The Pendulum Foundation and The Post Traumatic Growth Association. The product, bred by Aurora's genetics business Occo and derived from Chemdawg, OG18 and Skunk genetics, contains 20-26% THC and is available in 5g and 15g dried flower formats as well as exclusive pre-rolls for veteran medical patients.MjbizdailyLabeling issues lead to MedReleaf cannabis recall in QuebecMedReleaf Corp. is recalling two lots of Island Sweet Skunk cannabis sold in Quebec under the San Rafael '71 brand for incorrect labeling. The labels misstated THC levels, showing values 10 times lower than actual, and only 53 units were sold. No complaints or adverse reactions have been reported.PR NewswireAurora Cannabis Announces Financial Results for the First Quarter of Fiscal 2019Aurora Cannabis Inc. reported Q1 fiscal 2019 financial results for the quarter ended September 30, 2018, with revenue surging 260% year-over-year to $29.7 million, driven by strong patient growth following acquisitions of MedReleaf and CanniMed, increased product availability, and higher average selling prices. The company achieved a major milestone with the October 17, 2018 launch of Canada's adult-use cannabis market, recording $0.6 million in initial sales and capturing approximately 30% market share in Ontario within the first two weeks. Aurora has completed over 25 acquisitions totaling more than 500,000 kg of funded production capacity, including recent deals for MedReleaf, Anandia Laboratories, Agropro, Borela, and pending acquisition of ICC Labs to establish leadership across medical, wellness, and consumer-use market segments globally.NewswireAurora Cannabis Receives Production License for Aurora Eau Facility and Oils Production License for MedReleaf's Bradford FacilityAurora Cannabis received a Health Canada production license for its Aurora Eau facility in Quebec and an oils production license for MedReleaf's Bradford facility. The company now has seven production facilities with combined capacity exceeding 160,000 kg per annum, and total funded capacity over 500,000 kg per annum.Business InsiderThe marijuana industry is gripped by a deal frenzy, and PwC says some of the biggest players are guilty of moving in 'too many directions at once'PwC warns that Canadian marijuana cultivators' deal frenzy will create winners and losers, urging laser-focused long-term strategies. Constellation Brands invested nearly $4 billion in Canopy Growth, and Aurora acquired Medreleaf for $2.3 billion. PwC says LPs should avoid opportunistic events and build sustainable domestic businesses.PR NewswireCanadian Consumers to Have Big Impact on the Cannabis MarketA Deloitte report projects that Canadian consumers will spend up to USD 7.17 billion on cannabis in 2019, with legal recreational sales accounting for over half of this total following full legalization. Concurrently, several companies including WeedMD and MedReleaf have secured supply agreements with the Alberta Gaming, Liquor & Cannabis Commission to serve the new adult-use market. Additionally, GW Pharmaceuticals received FDA approval for Epidiolex, marking a significant regulatory milestone for cannabinoid-based therapeutics.